Intra-Cellular Therapies Inc. | Key People and Executives
Sharon Mates
Chairman, President & Chief Executive Officer
Robert L. van Nostrand
Lead Independent Director
Richard Alan Lerner
Independent Director
Rory B. Riggs
Independent Director
Chris D. Alafi
Independent Director
Joel S. Marcus
Independent Director
Sharon Mates
Chairman, President & Chief Executive Officer
Lawrence J. Hineline
Treasurer, Chief Financial & Accounting Officer
Suresh Durgam
Senior Vice President-Medical Affairs
Andrew Satlin
Chief Medical Officer & Executive Vice President
Robert E. Davis
Chief Scientific Officer & Senior Vice President
Kimberly E. Vanover
Vice President-Clinical Development
Allen A. Fienberg
Vice President-Business Development
Lawrence P. Wennogle
Vice President-Drug Discovery
John Sanchez
VP-Corporate Communications & Investor Relations
Michael Halstead
Secretary, Senior Vice President & General Counsel
Robert L. van Nostrand
Lead Independent Director
Richard Alan Lerner
Independent Director
Rory B. Riggs
Independent Director
Chris D. Alafi
Independent Director
Joel S. Marcus
Independent Director
| Address |
430 East 29th Street
New York New York 10016
United States
|
|
Employees
|
- |
| Website |
http://www.intracellulartherapies.com |
| Updated |
07/08/2019 |
| Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. |
